AIM2 and diabetic cardiomyopathy: Silencing of Aim2 decreased diameter of cardiomyocytes and collagen I and collagen III protein levels, attenuated cardiac dysfunction in vivo, and reduced GSDMD-NT-related pyroptosis in vitro, suggesting that AIM2 promotes diabetic cardiomyopathy by inducing pyroptotic cardiac cell death and ventricular remodeling (115).